Global Anticoagulant Market Size, Trends, & Growth Opportunity, By Drug Class, By Route of Administration, By Application, By Region & Forecast till 2027.
Description
Global Anticoagulant Market Size, Trends, & Growth Opportunity, By Drug Class, By Route of Administration, By Application, By Region & forecast till 2027.
Global Anticoagulant Market
Global Anticoagulants market was valued at US$ 34.0 billion in 2021 and is anticipated to reach at USD 60.8 billion by 2027 at a CAGR 10.2% from 2022-2027.
Anticoagulant drugs (also called as blood thinner) are chemical substances prevent or reduce blood and increase the blood clotting time. These drugs are chiefly used for high risk of blood clots in various medical conditions such as atrial fibrillation, deep vein thrombosis, myocardial infraction, pulmonary embolism, stroke and others.
Market Drivers
The Global anticoagulant industry is expected to show remarkable growth in the upcoming period due to increasing incidence of venous thromboembolism (VTE) and cardiovascular disorders, increasing adoption of novel oral anticoagulants, and rise in knowledge of NOACs in developing countries. Additionally, rise in number of obese and elderly people, higher unmet needs flow in demand of novel therapeutics promote the market growth. Oral anticoagulants market has observed the steady growth and there is fast expansion in product productions. Over the past decade, more patient-friendly, better compliant dosage form improved demand for oral coagulants market.
Market Restraints
Higher price of NOACs and lack of antidots for NOACs hamper the anticoagulant market. The novel oral anticoagulants are new class of anticoagulant drugs. NOCs have major pharmacologic benefit over warfarin, such as fast onset and offset of action, minimum drug interactions, and predictable pharmacokinetics. Although, these novel drugs have higher price and lead to rise in healthcare costs that may limit their adoption and in turn impede the anticoagulant market growth.
Market segmentation
The Global Anticoagulants market is segmented into Drug Class, route of administration, Application.
By Drug Class such as NOACs (Eliquis, Bevyxxa, Xarelto, Savaysa & lixiana, Pradaxa), Heparin & LMWH, Vitamin K Antagonist, Others. By Route of Administration such as Oral anticoagulant, Injectable anticoagulant. By Application such as Atrial fibrillation & heart attack, Stroke, Deep vein thrombosis (DVT), Pulmonary embolism (PE), Others.
Regional Analysis
The Global Anticoagulants market is segmented into five regions North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America brings about a revenue of USD 10.10 billion in 2018 and is expected to turn up superior in the global market during the forecast period. Asia Pacific is anticipated to witness the highest growth in the market value. Europe is anticipated to witness noteworthy growth in the market due to cardiovascular disease causes more than half of all deaths across the region, that is resulting in the higher adoption of blood thinning medications.
Key Players
Various Key Players are listed in this report such as Boehringer Ingelheim, BMS, Johnson & Johnson, Sanofi, Pfizer Inc., AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals, CSL Behring.
Market Taxonomy
By Drug Class
Bevyxxa
Xarelto
Savaysa & lixiana
Pradaxa
Global Anticoagulant Market
Global Anticoagulants market was valued at US$ 34.0 billion in 2021 and is anticipated to reach at USD 60.8 billion by 2027 at a CAGR 10.2% from 2022-2027.
Anticoagulant drugs (also called as blood thinner) are chemical substances prevent or reduce blood and increase the blood clotting time. These drugs are chiefly used for high risk of blood clots in various medical conditions such as atrial fibrillation, deep vein thrombosis, myocardial infraction, pulmonary embolism, stroke and others.
Market Drivers
The Global anticoagulant industry is expected to show remarkable growth in the upcoming period due to increasing incidence of venous thromboembolism (VTE) and cardiovascular disorders, increasing adoption of novel oral anticoagulants, and rise in knowledge of NOACs in developing countries. Additionally, rise in number of obese and elderly people, higher unmet needs flow in demand of novel therapeutics promote the market growth. Oral anticoagulants market has observed the steady growth and there is fast expansion in product productions. Over the past decade, more patient-friendly, better compliant dosage form improved demand for oral coagulants market.
Market Restraints
Higher price of NOACs and lack of antidots for NOACs hamper the anticoagulant market. The novel oral anticoagulants are new class of anticoagulant drugs. NOCs have major pharmacologic benefit over warfarin, such as fast onset and offset of action, minimum drug interactions, and predictable pharmacokinetics. Although, these novel drugs have higher price and lead to rise in healthcare costs that may limit their adoption and in turn impede the anticoagulant market growth.
Market segmentation
The Global Anticoagulants market is segmented into Drug Class, route of administration, Application.
By Drug Class such as NOACs (Eliquis, Bevyxxa, Xarelto, Savaysa & lixiana, Pradaxa), Heparin & LMWH, Vitamin K Antagonist, Others. By Route of Administration such as Oral anticoagulant, Injectable anticoagulant. By Application such as Atrial fibrillation & heart attack, Stroke, Deep vein thrombosis (DVT), Pulmonary embolism (PE), Others.
Regional Analysis
The Global Anticoagulants market is segmented into five regions North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America brings about a revenue of USD 10.10 billion in 2018 and is expected to turn up superior in the global market during the forecast period. Asia Pacific is anticipated to witness the highest growth in the market value. Europe is anticipated to witness noteworthy growth in the market due to cardiovascular disease causes more than half of all deaths across the region, that is resulting in the higher adoption of blood thinning medications.
Key Players
Various Key Players are listed in this report such as Boehringer Ingelheim, BMS, Johnson & Johnson, Sanofi, Pfizer Inc., AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals, CSL Behring.
Market Taxonomy
By Drug Class
- NOACs
Bevyxxa
Xarelto
Savaysa & lixiana
Pradaxa
- Heparin & LMWH
- Vitamin K Antagonist
- Others
- Oral anticoagulant
- Injectable anticoagulant.
- Atrial fibrillation & heart attack
- Stroke
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Others.
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa.
Table of Contents
- 1 Introduction
- 1.1 Objective of the Study
- 1.2 Market definition
- 1.3 Market Scope
- 2 Research Methodology
- 2.1 Data Mining
- 2.2 Validation
- 2.3 Primary Interviews
- 2.4 List of Data Sources
- 3 Executive Summary
- 4 Global Anticoagulant Market Outlook
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
- 5 Global Anticoagulant Market, By Drug Class
- 5.1 Y-o-Y Growth Comparison, By Drug Class
- 5.2 Global Anticoagulant Market Share Analysis, By Drug Class
- 5.3 Global Anticoagulant Market Size and Forecast, By Drug Class
- 5.3.1 NOACs
- 5.3.1.1 Eliquis
- 5.3.1.2 Bevyxxa
- 5.3.1.3 Xarelto
- 5.3.1.4 Savaysa & lixiana
- 5.3.1.5 Pradaxa
- 5.3.2 Heparin & LMWH
- 5.3.4 Vitamin K Antagonist
- 5.3.5 Others
- 6 Global Anticoagulant Market, By Route of Administration
- 6.1 Y-o-Y Growth Comparison, By Route of Administration
- 6.2 Global Anticoagulant Market Share Analysis, By Route of Administration
- 6.3 Global Anticoagulant Market Size and Forecast, By Route of Administration
- 6.3.1 Oral anticoagulant
- 6.3.2 Injectable anticoagulant.
- 7 Global Anticoagulant Market, By Application
- 7.1 Y-o-Y Growth Comparison, By Application
- 7.2 Global Anticoagulant Market Share Analysis, By Application
- 7.3 Global Anticoagulant Market Size and Forecast, By Application
- 7.3.1 Atrial fibrillation & heart attack
- 7.3.2 Stroke
- 7.3.3 Deep vein thrombosis (DVT)
- 7.3.4 Pulmonary embolism (PE)
- 7.3.5 Others.
- 8 Global Anticoagulant Market, By Region
- 8.1 Global Anticoagulant Market Share Analysis, By Region
- 8.2 Global Anticoagulant Market Share Analysis, By Region
- 8.3 Global Anticoagulant Market Size and Forecast, By Region
- 9 North America Immunoassay Market Analysis and Forecast (2022-2027)
- 9.1 Introduction
- 9.2 North America Immunoassay Market Share Analysis, By Drug Class
- 9.3 North America Immunoassay Market Size and Forecast, By Route of Administration
- 9.4 North America Immunoassay Market Size and Forecast, By Application
- 9.5 North America Immunoassay Market Size and Forecast, By Country
- 9.5.1 U.S.
- 9.5.2 Canada
- 9.5.3 Mexico
- 10 Europe Immunoassay Market Analysis and Forecast (2022-2027)
- 10.1 Introduction
- 10.2 Europe Immunoassay Market Share Analysis, By Drug Class
- 10.3 Europe Immunoassay Market Size and Forecast, By Route of Administration
- 10.4 Europe Immunoassay Market Size and Forecast, By Application
- 10.5 Europe Immunoassay Market Size and Forecast, By Country
- 10.5.1 Germany
- 10.5.2 France
- 10.5.3 UK
- 10.5.4. Rest of Europe
- 11 Asia Pacific Immunoassay Market Analysis and Forecast (2022-2027)
- 11.1 Introduction
- 11.2 Asia Pacific Immunoassay Market Share Analysis, By Drug Class
- 11.3 Asia Pacific Immunoassay Market Size and Forecast, By Route of Administration
- 11.4 Asia Pacific Immunoassay Market Size and Forecast, By Application
- 11.5 Asia Pacific Immunoassay Market Size and Forecast, By Country
- 11.5.1 China
- 11.5.2 Japan
- 11.5.3 India
- 11.5.4. Rest of Asia Pacific
- 12 Latin America Immunoassay Market Analysis and Forecast (2022-2027)
- 12.1 Introduction
- 12.2 Latin America Immunoassay Market Share Analysis, By Drug Class
- 12.3 Latin America Immunoassay Market Size and Forecast, By Route of Application
- 12.4 Latin America Immunoassay Market Size and Forecast, By Application
- 12.5 Latin America Immunoassay Market Size and Forecast, Country
- 12.5.1. Brazil
- 12.5.2. Rest of Latin America
- 13 Middle East Immunoassay Market Analysis and Forecast (2022-2027)
- 13.1 Introduction
- 13.2 Middle East Immunoassay Market Share Analysis, By Drug Class
- 13.3 Middle East Immunoassay Market Size and Forecast, By Route of Administration
- 13.4 Middle East Immunoassay Market Size and Forecast, By Application
- 13.5 Middle East Immunoassay Market Size and Forecast, By Country
- 13.5.1. Saudi Arabia
- 13.5.2. UAE
- 13.5.3. Egypt
- 13.5.4. Kuwait
- 13.5.5. South Africa
- 14 Competitive Analysis
- 14.1 Competition Dashboard
- 14.2 Market share Analysis of Top Vendors
- 14.3 Key Development Strategies
- 15 Company Profiles
- 15.1 Boehringer Ingelheim
- 15.1.1 Overview
- 15.1.2 Products
- 15.1.3 Key Financials
- 15.1.4 Business Segment & Geographic Overview
- 15.1.5 Key Market Developments
- 15.1.6 Key Strategies
- 15.2 BMS
- 15.2.1 Overview
- 15.2.2 Products
- 15.2.3 Key Financials
- 15.2.4 Business Segment & Geographic Overview
- 15.2.5 Key Market Developments
- 15.2.6 Key Strategies
- 15.3 Johnson & Johnson
- 15.3.1 Overview
- 15.3.2 Products
- 15.3.3 Key Financials
- 15.3.4 Business Segment & Geographic Overview
- 15.3.5 Key Market Developments
- 15.3.6 Key Strategies
- 15.4 Sanofi
- 15.4.1 Overview
- 15.4.2 Products
- 15.4.3 Key Financials
- 15.4.4 Business Segment & Geographic Overview
- 15.4.5 Key Market Developments
- 15.4.6 Key Strategies
- 15.5 Pfizer Inc
- 15.5.1 Overview
- 15.5.2 Products
- 15.5.3 Key Financials
- 15.5.4 Business Segment & Geographic Overview
- 15.5.5 Key Market Developments
- 15.5.6 Key Strategies
- 15.6 AstraZeneca
- 15.6.1 Overview
- 15.6.2 Products
- 15.6.3 Key Financials
- 15.6.4 Business Segment & Geographic Overview
- 15.6.5 Key Market Developments
- 15.6.6 Key Strategies
- 15.7 Bayer
- 15.7.1 Overview
- 15.7.2 Products
- 15.7.3 Key Financials
- 15.7.4 Business Segment & Geographic Overview
- 15.7.5 Key Market Developments
- 15.7.6 Key Strategies
- 15.8 Cellceutix
- 15.8.1 Overview
- 15.8.2 Products
- 15.8.3 Key Financials
- 15.8.4 Business Segment & Geographic Overview
- 15.8.5 Key Market Developments
- 15.8.6 Key Strategies
- 15.9 Cosmo Pharmaceuticals
- 15.9.1 Overview
- 15.9.2 Products
- 15.9.3 Key Financials
- 15.9.4 Business Segment & Geographic Overview
- 15.9.5 Key Market Developments
- 15.9.6 Key Strategies
- 15.10 CSL Behring
- 15.10.1 Overview
- 15.10.2 Products
- 15.10.3 Key Financials
- 15.10.4 Business Segment & Geographic Overview
- 15.10.5 Key Market Developments
- 15.10.6 Key Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
